We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
- Authors
Sorrell, April D; Alonzo, Todd A; Hilden, Joanne M; Gerbing, Robert B; Loew, Thomas W; Hathaway, Lois; Barnard, Dorothy; Taub, Jeffrey W; Ravindranath, Yaddanapudi; Smith, Franklin O; Arceci, Robert J; Woods, William G; Gamis, Alan S
- Abstract
Children who are treated for myeloid leukemia associated with Down syndrome (DS) experience superior survival compared with children who have myeloid leukemia without DS. To maintain excellent outcomes while avoiding toxicity, the Children's Oncology Group (COG) conducted the phase 3 trial COG A2971, the first trial solely designed to provide uniform treatment of myeloid leukemia in North American children with DS. A2971 eliminated 2 induction drugs and 3 months of maintenance therapy from the standard-timing regimen of dexamethasone, cytarabine, 6-thioguanine, etoposide, and rubidomycin/daunomycin (DCTER) used in the previous study (Children's Cancer Group [CCG] 2891).
- Publication
Cancer, 2012, Vol 118, Issue 19, p4806
- ISSN
1097-0142
- Publication type
Journal Article
- DOI
10.1002/cncr.27484